Simon G Wong
Overview
Explore the profile of Simon G Wong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
29
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wong S, Ramsden D, Dallas S, Fung C, Einolf H, Palamanda J, et al.
Drug Metab Dispos
. 2020 Nov;
49(1):94-110.
PMID: 33139460
Translational and ADME Sciences Leadership Group Induction Working Group (IWG) presents an analysis on the time course for cytochrome P450 induction in primary human hepatocytes. Induction of CYP1A2, CYP2B6, and...
2.
Rescourio G, Gonzalez A, Jabri S, Belmontes B, Moody G, Whittington D, et al.
J Med Chem
. 2019 Nov;
62(22):10258-10271.
PMID: 31736296
Overexpression of the antiapoptotic protein Mcl-1 provides a survival advantage to some cancer cells, making inhibition of this protein an attractive therapeutic target for the treatment of certain types of...
3.
Wang J, Takahashi R, DeMent K, Gustafson A, Kenny J, Wong S, et al.
Anal Biochem
. 2018 Jul;
556:85-90.
PMID: 29959909
A novel and rapid method to determine the potency of inhibitors for tryptophan 2, 3-dioxygenase (TDO2) activities in human and preclinical species was successfully developed and validated utilizing LC-MS/MS. Previously...
4.
Wong S, Lee M, Wong B
Xenobiotica
. 2016 Mar;
46(11):953-66.
PMID: 26956546
1. The utility of two abbreviated, higher-throughput assays [IC50-shift and the loss of activity (LOA) assay] to evaluate time-dependent inhibition (TDI) of 24 structurally related compounds was compared. 2. Good...
5.
Henne K, Tran T, VandenBrink B, Rock D, Aidasani D, Subramanian R, et al.
Drug Metab Dispos
. 2012 Apr;
40(7):1429-40.
PMID: 22517972
CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharmacokinetics in humans. Although in vitro activity loss assays failed to...
6.
Wong S
Curr Drug Metab
. 2011 May;
12(9):871-90.
PMID: 21619522
As the prevalence of polypharmacy increases with our aging population, the propensity for adverse drug-drug interactions arising from the altered metabolism of co-administered medicines remains an important consideration for drug...
7.
Wong S, Fan P, Subramanian R, Tonn G, Henne K, Johnson M, et al.
Drug Metab Dispos
. 2010 Jan;
38(5):841-50.
PMID: 20100816
The 2-methyl substituted indole, 2MI [2-(4-(4-(2,4-dichlorophenylsulfonamido)-2-methyl-1H-indol-5-yloxy)-3-methoxyphenyl)acetic acid] is a potent dual inhibitor of 1) chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells and 2) d-prostanoid receptor. During evaluation as a...
8.
Tonn G, Wong S, Wong S, Johnson M, Ma J, Cho R, et al.
Drug Metab Dispos
. 2008 Dec;
37(3):502-13.
PMID: 19088267
(R)-N-{1-[3-(4-Ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]-pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxyphenyl)-acetamide (AMG 487) is a potent and selective orally bioavailable chemokine (C-X-C motif) receptor 3 (CXCR3) antagonist that displays dose- and time-dependent pharmacokinetics in human subjects after multiple oral dosing....